Tuesday, May 24, 2016 11:03:19 AM
Or how about way less than the estimated cost of ARGS facility, estimated at $25mm for 100,000 sq ft. And it's owned by ARGS shareholders (unlike Cognate, in which no NWBO shareholder has any ownership, except Linda Powers and her family).
How can you even begin to justify the costs? Seriously doc, it's clearly disturbing.
Am I an expert on GAMP facilities? Nope, but I can easily look at others doing similar things and see big discrepancies. IMUC doing their P2 trial in ndGBM with dendritic cell vaccines for $13.5mm w/ 124 randomized and 278 vaccines made? While NWBO spends $260mm (20 TIMES as much) and gets 300 randomized? I can see ARGS spending on their own plant (that shareholders actually OWN) almost 40% larger than Cognate's planned total size post expansion and see vast discrepancies in cost ($25mm total). I can see Cognate doubling from 35,000 to 70,000 for $9mm.
Where did $100mm in CASH go?
"Think for yourselves and let others enjoy the privilege to do so, too."
-Voltaire
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM